Parliament Panel Calls for Overhaul of CDSCO Amid Drug Approval Delays
A parliamentary panel has strongly criticized the Central Drugs Standard Control Organization (CDSCO) for significant delays in drug approvals and has called for a comprehensive overhaul of the regulatory body. The panel's recommendations highlight the ur
CdscoDrug RegulationPharmaceutical IndustryHealthcareParliament PanelReal EstateMar 14, 2025
The report, which was tabled in Parliament, states that the CDSCO has been consistently failing to meet its regulatory obligations. The panel found that the agency has been unable to provide timely approvals for new drugs and medical devices, leading to delays in the availability of essential medicines to patients. This has not only affected patient care but has also hampered the growth of the pharmaceutical industry in India.
One of the key issues highlighted by the panel is the shortage of qualified personnel at the CDSCO. The regulatory body is currently understaffed, with a significant number of positions remaining vacant. This has led to a backlog of applications for drug approvals, which has further exacerbated the delays. The panel has recommended that the government immediately take steps to fill these vacancies and enhance the capacity of the CDSCO.
The panel also criticized the CDSCO for its lack of transparency and accountability. It was found that the regulatory body does not have a clear and transparent process for drug approvals, which has led to confusion and mistrust among stakeholders. The panel has recommended that the CDSCO adopt a more transparent and accountable mechanism for drug approvals, including the establishment of an independent review board to oversee the process.
In addition to these issues, the panel has also raised concerns about the CDSCO's handling of adverse events related to drugs and medical devices. The report states that the regulatory body has been slow in responding to reports of adverse events and has failed to take adequate measures to ensure patient safety. The panel has recommended that the CDSCO develop a robust system for monitoring and responding to adverse events, including the establishment of a dedicated surveillance unit.
The parliamentary panel has urged the government to take immediate action on its recommendations to address the issues facing the CDSCO. The panel has emphasized the importance of a strong and efficient regulatory body to ensure the safety and efficacy of pharmaceutical products in India. The recommendations, if implemented, could go a long way in improving the functioning of the CDSCO and restoring public confidence in the regulatory system.
In response to the panel's report, the Ministry of Health and Family Welfare has stated that it is committed to addressing the issues raised and will take the necessary steps to strengthen the CDSCO. The ministry has also indicated that it will explore the possibility of setting up a new regulatory framework to enhance the efficiency and transparency of the drug approval process.
The CDSCO plays a crucial role in India's healthcare system by ensuring that all pharmaceutical products in the market are safe and effective. However, the recent report by the parliamentary panel highlights the urgent need for reforms to address the regulatory body's shortcomings. The recommendations, if implemented, could help to streamline the drug approval process, improve patient care, and boost the growth of the pharmaceutical industry in India.
In conclusion, the parliamentary panel's call for an overhaul of the CDSCO is a significant step towards improving the regulatory framework for pharmaceutical products in India. It is hoped that the government will take proactive measures to address the issues raised and ensure that the CDSCO is equipped to meet the challenges of a rapidly evolving healthcare landscape.
Frequently Asked Questions
What is the Central Drugs Standard Control Organization (CDSCO)?
The Central Drugs Standard Control Organization (CDSCO) is India's primary regulatory body responsible for ensuring the safety, efficacy, and quality of pharmaceutical products. It is tasked with the approval of new drugs, medical devices, and cosmetics, as well as the monitoring of adverse events related to these products.
Why has the CDSCO been criticized by the parliamentary panel?
The parliamentary panel has criticized the CDSCO for significant delays in drug approvals, a shortage of qualified personnel, lack of transparency in its operations, and inadequate handling of adverse events related to drugs and medical devices.
What are the key recommendations of the parliamentary panel for the CDSCO?
The key recommendations include filling vacant positions, enhancing the capacity of the CDSCO, adopting a more transparent and accountable mechanism for drug approvals, and developing a robust system for monitoring and responding to adverse events.
How important is the CDSCO in India's healthcare system?
The CDSCO plays a crucial role in India's healthcare system by ensuring that all pharmaceutical products in the market are safe and effective. It is responsible for the approval and regulation of drugs, medical devices, and cosmetics, which are essential for patient care.
What steps has the government taken in response to the panel's recommendations?
The Ministry of Health and Family Welfare has stated that it is committed to addressing the issues raised by the parliamentary panel and will take necessary steps to strengthen the CDSCO. The ministry is exploring the possibility of setting up a new regulatory framework to enhance the efficiency and transparency of the drug approval process.
Related News Articles
MahaRERA Cracks Down on 628 Housing Projects for Non-Compliance
The Maharashtra Real Estate Regulatory Authority has taken action against 628 housing projects for not displaying registration numbers and QR codes in advertising materials.
Valor Estate and Macrotech Developers Join Forces for Luxury Mumbai Residential Project
Valor Estate's partnership with Macrotech Developers marks a significant milestone in their strategic growth plan, unlocking a prime 5.4-acre land parcel in Mumbai.
Colt DCS to Invest Rs 8,500 Cr in Navi Mumbai Hyperscale Data Centre
Fidelity-backed Colt DCS is planning to set up a large hyperscale data centre in Navi Mumbai with an investment of around Rs 8,500 crore, making it a hyperscale and enterprise solution data centre campus.
Flex Spaces to Dominate India's Office Market: Over 80% Occupiers Plan to Expand Through Flexible Workspaces
India's office market is witnessing a significant shift towards flexible workspaces, with over 80% occupiers planning to expand their office portfolio through flex spaces in the next few years.
Noida Authority Files EOW Complaint Against Logix Developers for Real Estate Violations
The Noida Authority has taken a tough stance on real estate irregularities by lodging an EOW (Economic Offences Wing) complaint against Logix Developers. This move signals the authority's commitment to maintaining transparency and accountability in the co
Proud Real Estate Launches Romm Convent: The Ultimate Luxury Wellness Residence in Bangkok
BANGKOK, THAILAND - Media OutReach Newswire - 30 December 2024 - In the heart of Bangkok’s prestigious Convent-Sathorn area, Proud Real Estate Plc. introduces Romm Convent, a luxurious and wellness-focused residence designed for discerning urbanites.